Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Gwolf who wrote (2898)	7/9/1998 2:22:00 PM
From: dwlima	Read Replies (1) \| Respond to of 5402

i saw that baxter developed Hemasist (sp?) and published its trial results from abroad 12 months ago. side affects were reported limited. what has been the result of this....do they sell it now? this was probably mentioned before...but i did not see this in prior posts. thanks

To: Gwolf who wrote (2898)	7/9/1998 6:38:00 PM
From: drdan	Read Replies (2) \| Respond to of 5402

g(may I call you that?<gg>), you are right that surfactant is a vital part of the drug. However, it does not play a role in the actual delivery and release of 02 to the cells. it is a lipid -based compound(fatty material) that reduces the surface tension of objects so that they do not collapse under low pressure.Think of it as a material that, if it coated the inside of a balloon enough, it would prevent the balloon from total collapse when there was little air in it. It does nothing else.In pher02 it will keep all the molecules from collapsing on themselves in solution, thereby causng the potential for clots.THAT is where it plays the vital role.